TY - JOUR
T1 - Early initiation of antiretroviral therapy for people newly diagnosed with HIV infection in Australia
T2 - trends and predictors, 2004–2015
AU - McManus, Hamish
AU - Callander, Denton
AU - Donovan, Basil
AU - Russell, Darren B.
AU - O'Connor, Catherine C.
AU - Davies, Stephen C.
AU - Lewis, David A.
AU - Hellard, Margaret E
AU - Chen, Marcus Y
AU - Petoumenos, Kathy
AU - Varma, Rick
AU - Cogle, Aaron
AU - Boyd, Mark Alastair
AU - Grulich, Andrew
AU - Pollard, James
AU - Medland, Nick
AU - Fairley, Christopher K
AU - Guy, Rebecca J.
PY - 2019/4/1
Y1 - 2019/4/1
N2 -
Objectives: To determine trends in and predictors of early treatment for people newly diagnosed with human immunodeficiency virus (HIV) infection in Australia. Design, setting: Retrospective cohort analysis of routinely collected longitudinal data from 44 sexual health clinics participating in the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance (ACCESS) program. Participants: Patients diagnosed with HIV infections, January 2004 – June 2015. Main outcome measures: Commencement of antiretroviral therapy within 6 months of HIV diagnosis (early treatment); demographic, clinical, and risk group characteristics of patients associated with early treatment; trends in early treatment, by CD4
+
cell count at diagnosis. Results: 917 people were diagnosed with HIV infections, their median age was 34 years (interquartile range [IQR]: 27–43 years), and 841 (92%) were men; the median CD4
+
cell count at diagnosis was 510 cells/μL (IQR, 350–674 cells/μL). The proportion of patients who received early treatment increased from 17% (15 patients) in 2004–06 to 20% (34 patients) in 2007–09, 34% (95 patients) in 2010–12, and 53% (197 patients) in 2013–15 (trend, P < 0.001). The probability of early treatment, which increased with time, was higher for patients with lower CD4
+
cell counts and higher viral loads at diagnosis. Conclusions: The proportion of people newly diagnosed with HIV in sexual health clinics in Australia who received treatment within 6 months of diagnosis increased from 17% to 53% during 2004–2015, reflecting changes in the CD4
+
cell count threshold in treatment guidelines. Nevertheless, further strategies are needed to maximise the benefits of treatment to prevent viral transmission and morbidity.
AB -
Objectives: To determine trends in and predictors of early treatment for people newly diagnosed with human immunodeficiency virus (HIV) infection in Australia. Design, setting: Retrospective cohort analysis of routinely collected longitudinal data from 44 sexual health clinics participating in the Australian Collaboration for Coordinated Enhanced Sentinel Surveillance (ACCESS) program. Participants: Patients diagnosed with HIV infections, January 2004 – June 2015. Main outcome measures: Commencement of antiretroviral therapy within 6 months of HIV diagnosis (early treatment); demographic, clinical, and risk group characteristics of patients associated with early treatment; trends in early treatment, by CD4
+
cell count at diagnosis. Results: 917 people were diagnosed with HIV infections, their median age was 34 years (interquartile range [IQR]: 27–43 years), and 841 (92%) were men; the median CD4
+
cell count at diagnosis was 510 cells/μL (IQR, 350–674 cells/μL). The proportion of patients who received early treatment increased from 17% (15 patients) in 2004–06 to 20% (34 patients) in 2007–09, 34% (95 patients) in 2010–12, and 53% (197 patients) in 2013–15 (trend, P < 0.001). The probability of early treatment, which increased with time, was higher for patients with lower CD4
+
cell counts and higher viral loads at diagnosis. Conclusions: The proportion of people newly diagnosed with HIV in sexual health clinics in Australia who received treatment within 6 months of diagnosis increased from 17% to 53% during 2004–2015, reflecting changes in the CD4
+
cell count threshold in treatment guidelines. Nevertheless, further strategies are needed to maximise the benefits of treatment to prevent viral transmission and morbidity.
KW - Epidemiologic measurements
KW - Immunotherapies
KW - Prevention and control
UR - http://www.scopus.com/inward/record.url?scp=85062992986&partnerID=8YFLogxK
U2 - 10.5694/mja2.50006
DO - 10.5694/mja2.50006
M3 - Article
AN - SCOPUS:85062992986
SN - 0025-729X
VL - 210
SP - 269
EP - 275
JO - The Medical Journal of Australia
JF - The Medical Journal of Australia
IS - 6
ER -